This Health Technology Assessment was commissioned by the "National system for the introduction of new health technologies within the specialist health service". The aim of this report was to assess the effect and cost-effectiveness of the disease modifying medicines used in Norway for patients with relapsing remitting multiple sclerosis (dimethyl fumarate, teriflunomide, interferon beta, peg-interferon, glatiramer acetate, natalizumab, fingolimod, and alemtuzumab).
http://ift.tt/2u6rrQY
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου